Research programme: cancer therapeutics - Shanghai Hengrui Pharmaceuticals
Latest Information Update: 16 Jul 2016
At a glance
- Originator Shanghai Hengrui Pharmaceutical
- Class Pyrroles; Vinca alkaloids
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; KIF11 protein inhibitors; Vascular endothelial growth factor receptor-2 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in China
- 10 Apr 2008 Preclinical trials in Cancer in China (unspecified route)